Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been used in the treatment of type 2 diabetes mellitus (T2DM) to inhibit renal glucose reabsorption and thereby increase urinary glucose loss.